培美曲塞联合顺铂治疗晚期非小细胞肺癌的疗效分析  

Clinical Observation on the Effect of Pemetrexed for Treating Advanced Non-small Cell Lung Cancer

作　　者：刘晓华[1] 肖泽民[1] 郑江[1] 

机构地区：[1]湖南省常德市第一人民医院肿瘤科,湖南常德415003

出　　处：《医学临床研究》2009年第11期2083-2085,共3页Journal of Clinical Research

摘　　要：【目的】观察培美曲塞联合顺铂治疗晚期非小细胞肺癌（NSCLC）的临床疗效和毒性反应。【方法】34例Ⅲ～Ⅳ期NSCLC患者均经病理组织学和（或）细胞学检查确诊。培美曲塞联合顺铂治疗后评价疗效。[结果]34例患者均可评价，获得完全缓解CR3例，部分缓解PR12例，有效率为44．1％（15／34）。最主要的毒副反应为白细胞及血小板降低，但均可耐受。【结论】培美曲塞联合顺铂治疗老年中晚期NSCLC有较好疗效，可明显改善患者生存质量，毒副反应轻，易于耐受。[Objective] To evaluate the clinical effect and toxicity of pemetrexed in treating advanced nonsmall cell lung eancer（NSCLC）. [Methods] Thirty four patients with advanced NSCLC diagnosed by pathology or cytology were enrolled into the study. After treatment of pemetrexed plus cisplatin, the curative effect was evaluated. [Results]Complete remission （CR） was found in 3 cases and partial remission （PR） was found in 12 cases. The total response rate was 44.1% （15/34）. One-year survival rate was 47.1%（16/34）. The main side effects were leucopenia and thrombocytopenia, but they were tolerable. [Conclusion] The regimen of pemetrexed plus cisptation is effective, safe and well tolerable in the treatment of advanced NSCLC. It can significantly improve the quality of life of the patient.

关 键 词：癌 非小细胞肺/药物疗法 顺铂/投药和剂量 药物疗法 联合 

分 类 号：R730.26[医药卫生—肿瘤]